Updated:
GC Biopharma
GC Biopharma originated in 1969 as Green Cross Corporation, founded by the late Chairman Huh Young-sup. Initially known for manufacturing and distributing...
GC Biopharma
GC Biopharma originated in 1969 as Green Cross Corporation, founded by the late Chairman Huh Young-sup. Initially known for manufacturing and distributing prescription and over-the-counter drugs, the company carved a specialized niche early on in plasma derivatives and vaccines. The firm has since evolved into a globally regulated biopharma corporate investor, with the founder's family — now led by Chairman Huh Il-sup and President EC Huh — maintaining control of its strategic direction from the headquarters in Yongin, Gyeonggi Province. The firm's investment posture is inseparable from its operations: capital is overwhelmingly directed into its own physical manufacturing and research infrastructure. Its asset mix spans commercial real estate, heavy industrial bio-production campuses, and a dedicated R&D center. The Hwasun, Ochang, and Osong plants anchor domestic production, while a plasma fractionation and labtech facility in San Antonio, Texas signals a deliberate North American production foothold. The Teaneck, New Jersey commercial office, led by CEO Woo Jin Lee, coordinates US-market access for its portfolio of biologic drugs and sterile-filled injectables. Beyond the balance-sheet deployments, the corporate entity supports a constellation of affiliated philanthropic foundations that blur the line with a family-office architecture. The Moga Museum of Art in Yongin houses a private collection, while the Mogam Institute for Biomedical Research and the Mogam Science Scholarship Foundation channel capital into long-horizon science and education initiatives. In March 2025, the firm maintained its commitment to rare disease therapies, advancing an FDA-approved plasma-derived treatment for hereditary angioedema through its US subsidiary (per public record, 2025). Structurally, GC Biopharma sits at the intersection of a publicly accountable pharmaceutical manufacturer and a family-influenced corporate investment vehicle. Unlike most family offices that allocate to third-party funds, GC Biopharma's deployment is direct: capital flows into owned operating assets, production lines, and clinical pipelines. The governance rests with a founding-family leadership core managing both commercial and philanthropic capital allocation as a single, operationally interconnected enterprise.
General information
Firm type
Corporate Investor
Year founded
1969
AUM
Undisclosed
Location
Region
Asia
Country
South Korea
City
Yongin-si
Corporate office
107 Ihyeon-ro 30beon-gil, Giheung-gu, Yongin-si, Gyeonggi-do, South Korea
Additional offices
Teaneck, NJ, USA
Principals
EC Huh
President
Woo Jin Lee
CEO of GC Biopharma USA
Sector focus
Frequently asked questions
Who runs investment and strategic decisions at GC Biopharma?
The founding Huh family retains control, with Chairman Huh Il-sup and President EC Huh at the top of a leadership structure that sets both commercial and capital-allocation strategy. Woo Jin Lee runs the US subsidiary from Teaneck, New Jersey. The executive group directs investment not into external funds but almost exclusively into owned manufacturing facilities, R&D centers, and affiliated non-profit foundational assets.
How does GC Biopharma structure its balance-sheet deployment?
GC Biopharma deploys capital through direct ownership of industrial bio-production facilities across South Korea and the United States. It owns five major plants — Hwasun, Ochang, Osong, and a San Antonio labtech facility — as well as a dedicated R&D complex in Yongin. This self-funded, vertically integrated model stands apart from third-party private equity or venture capital allocation.
What is the connection between GC Biopharma and the Moga Museum of Art?
The Moga Museum of Art in Yongin houses a private collection tied to the Huh family and GC Biopharma's founding legacy. Alongside the Mogam Institute for Biomedical Research and the Mogam Science Scholarship Foundation, it represents a web of philanthropic entities that operate adjacent to the corporate investor — though they are legally distinct non-profit organizations.
Is GC Biopharma a family office or a corporate operating company?
It operates as a corporate investor with strong family-office characteristics. The Huh family controls both the publicly accountable pharma manufacturing entity and a constellation of foundations. Unlike a generic single-family office that allocates to external managers, GC Biopharma feeds its capital into wholly owned operating assets, making its deployment model indistinguishable from its corporate balance sheet.
What is GC Biopharma's exposure to the United States?
GC Biopharma USA, headquartered in Teaneck, New Jersey, and led by CEO Woo Jin Lee, serves as the firm's commercial and regulatory hub for the American market. The firm also operates a plasma-processing and labtech facility in San Antonio, Texas, underscoring a physical production commitment to the US beyond a purely sales-and-distribution footprint.
Which therapeutic areas does GC Biopharma prioritize with its capital?
The firm concentrates on plasma derivatives, vaccines, and sterile-filled injectables. A significant recent example is its FDA-approved plasma-derived therapy for hereditary angioedema, which illustrates a long-term commitment to rare and specialty biologic treatments. Over-the-counter and prescription drugs round out the portfolio, but the capital-intensive plasma and vaccine segments dominate the fixed-asset investment.
Does GC Biopharma manage any external fund vehicles?
No. GC Biopharma does not operate a traditional fund-of-funds, venture arm, or third-party capital management business. Its deployment is direct and operational: capital flows into industrial plants, research facilities, and affiliated philanthropic structures. External investment alongside GPs or co-investors is not part of its publicly disclosed profile.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: